drugset
drugset / Trial / NCT03332849

Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus

NCT03332849 ↗

Phase 1 Unknown 60 enrolled Hanmi Pharmaceutical Company Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus

Timeline

Start
2015-07-28
Primary completion
2018-04-30
Completion
2018-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HM12470 Unknown — Subcutaneous

Indications

type 1 diabetes mellitus type 2 diabetes mellitus